Inactive Instrument

Enzymatica AB (publ) Share Price OTC Markets

EZYMF

SE0003943620

Valuation : Enzymatica AB (publ)

Market Cap	44Cr 38Cr 35Cr 32Cr 61Cr 4.2TCr 61Cr 421.14Cr 164.31Cr 2.12TCr 164.95Cr 161.36Cr 7.03TCr	P/E 2024	-5.73x	P/E 2025	-8.89x
Enterprise Value	41Cr 35Cr 33Cr 30Cr 57Cr 3.89TCr 57Cr 390.36Cr 152.3Cr 1.96TCr 152.9Cr 149.57Cr 6.51TCr	EV / Sales 2024	5.88x	EV / Sales 2025	7.96x
Free-Float	56.66%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news : Enzymatica AB (publ)

27/08	Enzymatica expands group management with two executives	FW
20/07	Enzymatica CFO Holger Lembrér buys shares for 110,000 kronor	FW
16/07	Enzymatica AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
16/07	Enzymatica cut revenue, but the loss also narrowed	FW
24/06	Enzymatica AB Provides Update On The Evidence Base For Coldzyme And PLOS ONE Expression Of Concern Regarding Berlin II Article	CI
24/06	Scientific paper on Enzymatica's Berlin II study receives an Expression of Concern, update	FW
23/06	Study of Enzymatica's cold spray Coldzyme gets a warning flag	FW
09/06	Enzymatica AB Announces Appointment of Joakim Tingström Nordin as Nordic Marketing and Sales Director, Effective August 2026	CI
09/06	Enzymatica appoints new Head of Marketing and Sales to drive Coldzyme growth in the Nordics	FW
28/04	Enzymatica Q1 operating loss narrows to SEK 13.6 million	RE
28/04	Enzymatica narrows losses	FW
28/04	Enzymatica AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
01/04	Enzymatica Marketing Executive sells shares worth over SEK 0.1 million	FW

More news

Analysts' recommendations : Enzymatica AB (publ)

19/24/19	Penser lowers motivated value for Enzymatica - raises required return to reflect risk	FW
26/24/26	Redeye lowers motivated value for Enzymatica to SEK 5.5 (6.0)	FW
20/24/20	Penser lowers Enzymaticas' motivated value	FW
08/23/08	Penser lowers motivated value for Enzymatica	FW
08/23/08	Redeye lowers motivated value for Enzymatica to SEK 6.0 (6.5)	FW

More recommendations

Press Releases : Enzymatica AB (publ)

27/08	Enzymatica strengthens its management team with commercial and scientific expertise	AQ
16/07	Quarterly report Q2/2026 Continued focus on international expansion and a stronger organization	AQ
24/06	The evidence base for ColdZyme remains unchanged – PLOS ONE notice concerns the presentation of the Berlin II article, not the evidence base for ColdZyme	AQ
09/06	Enzymatica appoints Marketing and Sales Director to accelerate ColdZyme’s continued growth in the Nordics	AQ
08/06	Enzymatica : partners with Unibet Rose Rockets to put ColdZyme in the Giro d’Italia race routine	PU

More press releases

Managers and Directors : Enzymatica AB (publ)

Manager	Title	Age	Since
Sana Alajmovic CEO	Chief Executive Officer	-	01/02/2026
Holger Lembrér DFI	Director of Finance/CFO	-	13/04/2026
Bjarki Stefánsson CTO	Chief Tech/Sci/R&D Officer	-	27/08/2026

Director	Title	Age	Since
Gudmundur Palmason CHM	Chairman	58	15/02/2016
Bengt Baron CHM	Chairman	64	19/12/2016
Mats K. Andersson BRD	Director/Board Member	71	19/12/2016

More insiders

Enzymatica AB (publ) is a Sweden-based life science company that develops and sells medical devices for infection-related diseases. The Company deals with research, development and sales of products based on enzyme technology and related activities. Enzymatica AB (publ) develops solutions that support the body's own defenses against virus, irritants and microorganisms. The Company offers products which are based on a barrier technology, includes marine enzymes. Enzymatica AB (publ) focuses on product development based on the tested and patented barrier technology used in the common cold product ColdZyme, a mouth spray that protects against colds, can help shorten the duration of the cold if used in the early stages of infection, relieves cold symptoms, and soothes sore throats.

Employees

Sector

Pharmaceuticals

Calendar

29/10 Earnings release - Q3 2026

More about the company

As early as today, start finding the best investment opportunities!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENZYMATICA AB (PUBL)	-9.63%	-50.94%	-	-	4.58Cr
ELI LILLY AND COMPANY	-0.13%	-6.44%	+60.47%	+112.05%	1,04700Cr
JOHNSON & JOHNSON	+0.85%	-0.81%	+52.77%	+63.15%	65TCr
ABBVIE INC.	-1.03%	-3.58%	+22.87%	+73.29%	45TCr
ROCHE HOLDING AG	-1.46%	-4.50%	+37.43%	+38.41%	35TCr
NOVARTIS AG	-0.72%	-2.89%	+21.86%	+36.79%	29TCr
ASTRAZENECA PLC	-1.19%	-2.21%	+1.35%	+12.29%	25TCr
AMGEN INC.	-1.05%	-1.57%	+51.40%	+68.55%	23TCr
NOVO NORDISK A/S	+0.08%	-1.78%	-17.64%	-54.29%	20TCr
GILEAD SCIENCES, INC.	-2.14%	-0.30%	+29.42%	+89.10%	18TCr
Average	-1.65%	-2.68%	+28.88%	+48.82%	40.66TCr
Weighted average by Cap.	-0.48%	-3.46%	+38.66%	+65.51%

	2024	2025
Net sales	4.56Cr 3.93Cr 3.68Cr 3.36Cr 6.33Cr 435.58Cr 6.35Cr 44Cr 17Cr 219.88Cr 17Cr 17Cr 729.08Cr	5.39Cr 4.64Cr 4.35Cr 3.98Cr 7.49Cr 515.17Cr 7.51Cr 52Cr 20Cr 260.06Cr 20Cr 20Cr 862.3Cr
Net income	-5.32Cr -4.58Cr -4.3Cr -3.92Cr -7.39Cr -508.25Cr -7.41Cr -51Cr -20Cr -256.56Cr -20Cr -20Cr -850.72Cr	-5.19Cr -4.47Cr -4.19Cr -3.83Cr -7.21Cr -495.93Cr -7.23Cr -50Cr -19Cr -250.34Cr -19Cr -19Cr -830.1Cr
Net Debt	-7.3Cr -6.29Cr -5.9Cr -5.38Cr -10Cr -697.8Cr -10Cr -70Cr -27Cr -352.24Cr -27Cr -27Cr -1.17TCr	-3.21Cr -2.77Cr -2.59Cr -2.37Cr -4.46Cr -306.9Cr -4.48Cr -31Cr -12Cr -154.92Cr -12Cr -12Cr -513.69Cr

Enzymatica AB (publ) Share Price OTC Markets

Stocks

EZYMF

SE0003943620

Pharmaceuticals

Valuation : Enzymatica AB (publ)

Latest news : Enzymatica AB (publ)

Analysts' recommendations : Enzymatica AB (publ)

Press Releases : Enzymatica AB (publ)

Quotes and Performance

Managers and Directors : Enzymatica AB (publ)

Other Pharmaceuticals

Financials

Company Profile